CLOZAPINE
Clinical safety rating: safe
Animal studies have demonstrated safety
Atypical antipsychotic; binds to dopamine D4, serotonin 5-HT2A, and adrenergic α2 receptors; weak D2 antagonist with rapid dissociation; also affects histaminergic and cholinergic receptors.
| Metabolism | Primarily by CYP1A2, with minor contributions from CYP2D6, CYP3A4, and CYP2C19. |
| Excretion | Approximately 50% of the dose is excreted in urine (30% as unchanged drug and metabolites) and 30% in feces via biliary elimination. |
| Half-life | Terminal elimination half-life is 8 to 12 hours (steady-state), but can range from 4 to 66 hours; requires dose adjustment in renal/hepatic impairment. |
| Protein binding | 97% bound to plasma proteins (mainly albumin and alpha-1-acid glycoprotein). |
| Volume of Distribution | Vd is 1.6 to 5.0 L/kg (average 2-5 L/kg), indicating extensive tissue distribution. |
| Bioavailability | Oral: 50-60% due to first-pass metabolism. |
| Onset of Action | Oral: 1-2 weeks for antipsychotic effect; maximal effect may take several weeks to months. |
| Duration of Action | Due to long half-life, effects persist for 24-48 hours after single dose; steady-state achieved in 5-7 days. |
| Molecular Weight | 326.83 |
Initial: 12.5 mg orally once or twice daily; titrate gradually by 25-50 mg/day to target dose 300-450 mg/day in divided doses; max 900 mg/day.
| Dosage form | TABLET |
| Renal impairment | No specific dose adjustment guidelines for renal impairment; use caution in severe impairment (GFR <30 mL/min) with slower titration and lower target doses. |
| Liver impairment | Child-Pugh class A: no adjustment; Child-Pugh class B: reduce dose by 50% and titrate slowly; Child-Pugh class C: contraindicated. |
| Pediatric use | Not FDA-approved for pediatric use; dosing off-label: initial 12.5 mg/day, titrate up to 25-50 mg/day increments; target 100-400 mg/day based on response; max 500 mg/day; weight-based: 0.15-0.5 mg/kg/day divided BID-TID, titrate to 3-6 mg/kg/day; max 9 mg/kg/day. |
| Geriatric use | Start at 12.5 mg once daily; titrate slowly by 12.5-25 mg increments; target 150-300 mg/day; monitor for orthostatic hypotension, sedation, and anticholinergic effects. |
| 1st trimester | Risk of congenital malformations, especially neural tube defects, may be elevated. Use only if benefit outweighs risk. |
| 2nd trimester | Monitor for gestational diabetes, weight gain, and blood dyscrasias. Consider dose adjustment due to altered pharmacokinetics. |
| 3rd trimester | Risk of neonatal withdrawal (irritability, feeding problems) and agranulocytosis. Taper near term if possible. |
Clinical note
Bone marrow suppressants may increase risk of agranulocytosis Can cause severe neutropenia and agranulocytosis requiring mandatory WBC monitoring.
| Placental transfer | Clozapine crosses the placenta (maternal-to-fetal ratio ~0.5-1.0). Minimal data on specific transfer dynamics. |
| Breastfeeding | Clozapine is excreted into breast milk in small amounts. Monitor infant for sedation, agranulocytosis (CBC), and neurodevelopmental effects. Benefit must outweigh risk. |
■ FDA Black Box Warning
Severe neutropenia/agranulocytosis; myocarditis and cardiomyopathy; seizures; orthostatic hypotension with syncope; increased mortality in elderly patients with dementia-related psychosis.
| Common Effects | Sedation |
| Serious Effects |
Myeloproliferative disordersHistory of clozapine-induced agranulocytosisSevere CNS depressionComatose statesUncontrolled epilepsy
| Precautions | Monitor CBC weekly for 6 months, then biweekly for 6 months, then monthly; monitor for myocarditis; titrate slowly; avoid in patients with uncontrolled epilepsy; risk of metabolic syndrome; anticholinergic toxicity; eosinophilia; withdrawal reactions. |
| Food/Dietary | Grapefruit and grapefruit juice may increase clozapine levels; avoid. Caffeine may increase clozapine levels; limit intake. Smoking induces CYP1A2, reducing clozapine levels; smoking cessation may increase levels. High-fat meals may increase clozapine absorption. Alcohol can potentiate CNS depression and hypotension. Avoid excessive tyramine-rich foods (e.g., aged cheese) if taking MAOIs concurrently, though MAOI combination is not typical with clozapine. |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) – Use with caution. |
| Teratogenic Risk | Clozapine is not associated with major congenital malformations in first trimester exposure but may cause gestational diabetes, weight gain, and preterm birth. Third trimester exposure risks include neonatal withdrawal symptoms (agitation, hypertonia, tremors, sedation) and possible extrapyramidal signs. |
| Fetal Monitoring | Monitor maternal white blood cell count and absolute neutrophil count (ANC) weekly for first 18 weeks, then every 2 weeks up to 1 year, then monthly due to agranulocytosis risk. Assess for gestational diabetes, weight gain, and blood pressure. Fetal monitoring includes growth scans and fetal movement counts. Newborns should be monitored for withdrawal symptoms and extrapyramidal signs for 48-72 hours post-delivery. |
| Fertility Effects | Clozapine can elevate prolactin levels less than other antipsychotics but may still cause menstrual irregularities, galactorrhea, and impaired ovulation. Hyperprolactinemia may reduce fertility. Weight gain and metabolic changes can also contribute to infertility. |
| Clinical Pearls | Mandatory ANC monitoring per REMS; weekly for first 6 months, then every 2 weeks for next 6 months, then monthly thereafter if counts stable. Risk of myocarditis especially in first 2 months; monitor for chest pain, dyspnea, fever. Orthostatic hypotension common; titrate slowly. Severe constipation can lead to ileus; use prophylactic bowel regimen. Concurrent benzodiazepines increase risk of respiratory depression and hypotension. Anticholinergic effects may worsen glaucoma or urinary retention. Neutropenia risk is higher in patients with low baseline WBC, ethnic neutropenia, or concurrent bone marrow suppressive drugs. |
| Patient Advice | You must have regular blood tests to monitor your white blood cell count before starting and during treatment. · Contact your doctor immediately if you develop fever, sore throat, mouth ulcers, or any signs of infection. · Rise slowly from sitting or lying positions to prevent dizziness or fainting due to low blood pressure. · Drink plenty of fluids and eat a high-fiber diet to prevent severe constipation; report any abdominal pain or lack of bowel movements. · Avoid alcohol, grapefruit juice, and smoking as they may affect how clozapine works. · Do not stop taking clozapine abruptly; dosage must be tapered under medical supervision. · If you experience chest pain, palpitations, shortness of breath, or flu-like symptoms early in treatment, seek immediate medical attention. · Clozapine can cause drowsiness; avoid driving or operating heavy machinery until you know how it affects you. · Tell your doctor about all medications you take, including over-the-counter drugs and supplements. · Report any uncontrolled urges (e.g., gambling, shopping, sex) as they may be side effects. |